Igor Lychagov Files SC 13D for Rezolve AI Limited
Ticker: RZLVW · Form: SC 13D · Filed: Aug 22, 2024 · CIK: 1920294
Sentiment: neutral
Topics: ownership-change, schedule-13d, beneficial-ownership
TL;DR
**Lychagov now owns a chunk of Rezolve AI. Big changes coming?**
AI Summary
Igor Lychagov filed a Schedule 13D on August 22, 2024, reporting beneficial ownership of Rezolve AI Limited. The filing indicates a change in ownership as of August 15, 2024. Lychagov's address is listed as c/o LakeShore International Management AG in Luzern, Switzerland.
Why It Matters
This filing signals a significant change in beneficial ownership for Rezolve AI Limited, which could impact the company's control and future strategic direction.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant stake-building or changes in control, which can introduce uncertainty and potential volatility for the company's stock.
Key Players & Entities
- Igor Lychagov (person) — Filing person reporting beneficial ownership
- Rezolve AI Limited (company) — Subject company
- LakeShore International Management AG (company) — Address for Igor Lychagov
- August 15, 2024 (date) — Date of event requiring filing
- August 22, 2024 (date) — Filing date
FAQ
What is the specific percentage of Rezolve AI Limited's ordinary shares that Igor Lychagov beneficially owns?
The provided text does not specify the exact percentage of shares owned by Igor Lychagov, only that he is filing a Schedule 13D to report beneficial ownership.
What was the specific event on August 15, 2024, that triggered this Schedule 13D filing?
The filing states 'August 15, 2024 (Date of Event which Requires Filing of this Statement)' but does not detail the specific event.
What is the business address of Rezolve AI Limited?
The business address of Rezolve AI Limited is 80 NEW BOND STREET, 3RD FLOOR, LONDON, W1S 1SB.
What is the CUSIP number for Rezolve AI Limited's ordinary shares?
The CUSIP number for Rezolve AI Limited's ordinary shares is G75398100.
Is this an amendment to a previous filing, or an initial Schedule 13D filing?
The filing is a Schedule 13D and the 'Amendment No.' field is blank, suggesting it is an initial filing or an amendment that does not require a specific amendment number in this context.
Filing Stats: 1,473 words · 6 min read · ~5 pages · Grade level 9.8 · Accepted 2024-08-22 17:00:50
Key Financial Figures
- $0.0001 — e of Issuer) Ordinary Share, par value $0.0001 (Title of Class of Securities) G75398
- $8,000,000 — lds convertible loan notes amounting to $8,000,000. As of August 15, 2024, these loan note
- $7 — of the Issuer at a conversion price of $7 per share, in accordance with the terms
- $25,833,079 — quire the securities reported herein is $25,833,079. These funds were obtained through the
Filing Documents
- tm2422488d1_sc13d.htm (SC 13D) — 35KB
- 0001104659-24-092039.txt ( ) — 36KB
Security and Issuer
Item 1. Security and Issuer. This statement on Schedule 13D relates to the Series A shares, Ordinary shares as well as convertible loan notes that can be converted into ordinary shares held by the Reporting Person of Rezolve AI Limited (the "Issuer"). The principal executive offices of the Issuer are located at Rezolve AI Limited, 5 New Street Square London EC4A 3TW, United Kingdom. The class of equity securities to which this statement relates are the Series A shares, Ordinary shares as well as the convertible loan notes that can be converted into ordinary shares of the Issuer. The par value of the Series A shares as well as the Ordinary shares is $ 0.0001. The Reporting Person beneficially owns 1,907,089 Series A shares and 32,863,911 Ordinary shares of the Issuer. In addition, the Reporting Person holds convertible loan notes amounting to $8,000,000. As of August 15, 2024, these loan notes may be converted into ordinary shares of the Issuer at the request of the Reporting Person. The conversion price will be the lower of a 30% discount to the IPO price or the last 12 months’ weighted average price. As of the IPO date of August 15, 2024, if fully converted, the loan notes would be converted into 1,632,653 ordinary shares of the Issuer at a conversion price of $7 per share, in accordance with the terms of the loan agreement.
Identity and Background
Item 2. Identity and Background. a. Igor Lychagov b. LakeShore International Management AG Obergrundstrasse 44 6003 Luzern, Switzerland Telephone: +41 41 368 10 90 c. The Reporting Person is currently co-founder and member of the board of Ornament Health AG, a healthcare technology company headquartered at Obergrundstrasse 44, 6003 Luzern, Switzerland. He was formerly a co-founder of Exness Group, a financial services firm with offices located at 1, Siafi Street, Porto Bello Business Center, Office 301, Limassol, 3042, Cyprus. d. During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). e. During the last five years, the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, as a result of which Reporting Person became or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Source or Amount of Funds or Other Consideration
Item 3. Source or Amount of Funds or Other Consideration. The total amount of funds used by the Reporting Person to acquire the securities reported herein is $25,833,079. These funds were obtained through the Reporting Person's professional activities, including earnings and dividends received. No loans or other forms of borrowed funds were used to finance the acquisition. CUSIP No. G75398100 13D Page 4 of 5 Pages
Purpose of Transaction
Item 4. Purpose of Transaction. The Reporting Person acquired the securities reported herein for investment purposes, specifically to gain exposure to the technology sector as part of his personal investment strategy, for passive investment purposes and without the intent to effect any change in management or control of the Issuer. Except as described in this Item 4 or would occur upon completion of any of the transactions discussed herein, as of the date of this statement the Reporting Person has no present plan or proposal that relates to or would result in any of the matters set forth in subsections (a) through (j) of Item 4 of Schedule 13D.
Interest in Securities of the Issuer
Item 5. Interest in Securities of the Issuer. a. The Reporting Person beneficially owns, together with loan notes that when fully converted translates into 1,632,653 ordinary shares, a total of 36,403,653 Ordinary shares of the Issuer, representing approximately 21.14% of the Issuer’s outstanding Ordinary shares. These include the previously held Series A shares, which have been reclassified as Ordinary shares, as well as ordinary shares and the loan notes that when fully converted translate into 1,632,653 ordinary shares. The percentage of 21.14% is based on 172,182,179 Ordinary shares outstanding as of 08/22/2024. b. The Reporting Person has sole voting power and sole dispositive power with respect to all of the shares reported herein. c. The Reporting Person has not engaged in any transactions involving the Issuer’s securities within the past 60 days. d. The Reporting Person does not beneficially own any other securities of the Issuer. e. The Reporting Person is not a member of any group that has filed this Schedule 13D.
Contracts, Arrangements, Understandings or Relationships
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. The Reporting Person served on the board of the Issuer from August 2019 until May 19, 2023, at which time he resigned from the board. Since his resignation in May 2023, the Reporting Person’s relationship with the Issuer has been solely as a shareholder and for passive investment purposes and without the intent to effect any change in management or control of the Issuer. He does not have any other contracts, arrangements, understandings, or relationships (legal or otherwise) concerning any securities of the Issuer, including but not limited to the transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, nor does he receive any material non-public information from the Issuer. Furthermore, the Reporting Person does not have any oversight, information, or control over the Issuer’s decisions and operations. As stated earlier, the Reporting Person holds convertible loan notes amounting to $8,000,000. These loan notes are convertible into shares of the Issuer at the request of the Reporting Person. The conversion price will be the lower of a 30% discount to the IPO price or the last 12 months’ weighted average price. As of the IPO date, if fully converted, the loan notes would be converted into 1,632,653 ordinary shares of the Issuer at a conversion price of $7 per share, in accordance with the terms of the loan agreement.
Material to Be Filed as Exhibits
Item 7. Material to Be Filed as Exhibits. None CUSIP No. G75398100 13D Page 5 of 5 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. /s/ Igor Lychagov Igor Lychagov Shareholder Title August 22, 2024 Date